Literature DB >> 12809529

Phosphotyrosyl mimetics in the development of signal transduction inhibitors.

Terrence R Burke1, Kyeong Lee.   

Abstract

Phosphotyrosyl (pTyr) residues play important roles in cellular signal transduction by facilitating recognition and binding necessary for critical protein-protein interactions, and for this reason pTyr motifs represent attractive starting points in the development of signaling antagonists. Although the pTyr phosphoryl moiety is central in these phenomena, its incorporation into signaling inhibitors is contraindicated due to enzymatic lability and limited bioavailability associated with phosphate esters. To address these limitations, an entire field of study has arisen devoted to the design and utilization of pTyr mimetics. This Account provides a perspective on the roles of pTyr residues in signal transduction and approaches to pTyr mimetic development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809529     DOI: 10.1021/ar020127o

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  19 in total

1.  Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK.

Authors:  Rong Huang; Hyunju Oh; Allison Arrendale; Victoria A Martin; Jacob Galan; Eric J Workman; Jane R Stout; Claire E Walczak; W Andy Tao; Richard F Borch; Robert L Geahlen
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

2.  Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form.

Authors:  Wen-Jian Qian; Terrence R Burke
Journal:  Amino Acids       Date:  2013-08-02       Impact factor: 3.520

3.  Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Suk-Youl Park; Ki-Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chem Biol       Date:  2013-10-10

4.  Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides.

Authors:  Fa Liu; Jung-Eun Park; Kyung S Lee; Terrence R Burke
Journal:  Tetrahedron       Date:  2009-11-21       Impact factor: 2.457

5.  Design and synthesis of a potential SH2 domain inhibitor bearing a stereodiversified 1,4-cis-enediol scaffold.

Authors:  Christine Marian; Rong Huang; Richard F Borch
Journal:  Tetrahedron       Date:  2011-12-30       Impact factor: 2.457

6.  Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.

Authors:  David Hymel; Terrence R Burke
Journal:  ChemMedChem       Date:  2017-01-09       Impact factor: 3.466

7.  Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.

Authors:  Wenjian Qian; Jung-Eun Park; Fa Liu; Kyung S Lee; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2012-05-26       Impact factor: 3.641

Review 8.  Grb2 signaling in cell motility and cancer.

Authors:  Alessio Giubellino; Terrence R Burke; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

9.  Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.

Authors:  Dusica Vidović; Stephan C Schürer
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

10.  Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase.

Authors:  Yuli Xie; Yidong Liu; Gangli Gong; Alison Rinderspacher; Shi-Xian Deng; Deborah H Smith; Udo Toebben; Effie Tzilianos; Lars Branden; Dusica Vidović; Caty Chung; Stephan Schürer; Lutz Tautz; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2008-04-08       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.